TP-06
Not Disclosed (Ophthalmic)
PreclinicalActive Discovery
Key Facts
Indication
Not Disclosed (Ophthalmic)
Phase
Preclinical
Status
Active Discovery
Company
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a public biopharma company that achieved a significant milestone with the 2023 FDA approval of XDEMVY for Demodex blepharitis, a common eyelid disease affecting millions. The company is now executing its commercial launch while advancing a pipeline of novel candidates, including TP-03 for Meibomian Gland Disease and TP-04 for rosacea, based on its targeted therapeutic approach. Tarsus's strategy is to identify and develop treatments for prevalent, underserved conditions, aiming to establish a leading position in medical dermatology and ophthalmology.
View full company profile